GlassScriptPhysician profile
Marshal A Blatt
NPI 1699882423
$41,226.27
in general payments reported to CMS, 2019-2025
36 companies · $6,562 in 2025
The $6,562 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,392 · 2021: $4,395 · 2022: $4,137 · 2023: $4,460 · 2024: $4,500 · 2025: $6,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,310.15 |
| Education | $211.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $7,354.75 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $6,553.27 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $2,810.44 | 2019-2022 | |
| Abbvie INC. | $2,791.42 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $2,430.60 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Teva Pharmaceuticals USA, INC. | $2,281.27 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $2,160.61 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $2,127.63 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $2,045.98 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,824.81 | 2020-2025 | Caplyta |
| Allergan, INC. | $1,714.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,071.93 | 2019-2025 | Trintellix |
| Avanir Pharmaceuticals, INC. | $866.04 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $785.70 | 2019-2025 | Fanapt |
| Tris Pharma INC | $732.56 | 2022-2025 | Dyanavel Xr |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $713.13 | 2022-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $589.19 | 2019-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $481.05 | 2024-2025 | Cobenfy |
| Indivior INC. | $416.65 | 2019-2024 | Perseris |
| Eisai INC. | $316.05 | 2020-2022 | |
| Corium, LLC | $250.20 | 2022-2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $223.75 | 2022-2025 | Quviviq, Quviviq |
| Neuronetics, INC. | $128.22 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $97.03 | 2019-2020 | |
| Shire North American Group INC | $85.84 | 2019 | |
| Jazz Pharmaceuticals INC. | $69.61 | 2021-2022 | |
| Neos Therapeutics, LP | $61.18 | 2019 | |
| Alfasigma USA, INC. | $61.07 | 2020 | |
| Boston Scientific Corporation | $39.24 | 2021-2022 | |
| Harmony Biosciences LLC | $32.67 | 2023 | Wakix |
| Sage Therapeutics, LLC | $28.95 | 2023 | |
| Bioxcel Therapeutics, INC. | $25.06 | 2023 | Igalmi |
| Bausch Health US, LLC | $19.51 | 2019 | |
| Adlon Therapeutics L.P. | $14.70 | 2020 | |
| Biogen, INC. | $14.39 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $6.80 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshal Blatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.